FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100027947> ?p ?o ?g. }

• W2100027947 endingPage "1238" @default.
• W2100027947 startingPage "1230" @default.
• W2100027947 abstract "Background. Uraemic bone disease is the result of a number of factors modulating bone formation and resorption in a complex manner. In the present study, the hypothesis tested was that the type of haemodialysis membrane used for renal replacement therapy might also play a role. Methods. We conducted a prospective, open study in 24 chronic haemodialysis patients who were randomized to dialysis treatment with either cellulosic (CELL group, n=11) or polyacrylonitrile (AN‐69 group, n=13) membrane for 9 months. Repeated determinations of plasma parameters reflecting bone turnover were done in all patients, and a bone biopsy in a subgroup at the start and end of study. Results. At the start, mean plasma intact parathyroid hormone levels were comparable between the two groups and they did not vary significantly at 9 months of treatment. Similarly, plasma bone‐specific alkaline phosphatase and osteocalcin (markers of bone formation), and cross‐laps (marker of bone resorption) remained unchanged. However, plasma insulin‐like growth factor‐I (IGF‐I) progressively decreased from 169 to 119 ng/ml in AN‐69 group (P<0.01), whereas it remained unchanged in CELL group. In addition, the levels of IGF binding protein (IGFBP)‐1 and IGFBP‐2 were increased while the levels of IGFBP‐5 were decreased in AN‐69 group. In the five patients of each group who had repeat bone biopsies, histomorphometric analysis showed a decrease in osteoblast surface, osteoclast surface and osteoclast number in AN‐69 group at 9 months, compared with baseline values measured at the start of the study. In contrast, all three parameters significantly increased in the CELL group at 9 months (P<0.001 for the difference between each of the three parameters).Bone formation rate decreased by 31% in the AN‐69 group, but increased by 50% in CELL group. However, this latter difference was not statistically significant. Plasma interleukin (IL)‐6 and soluble IL‐6 receptor levels did not change in the two groups of patients who had undergone bone biopsy. Conclusion. Dialysis with CELL membrane was associated with increased bone turnover whereas the use of AN‐69 membrane was associated with decreased bone turnover, suggesting a beneficial effect of the latter on high‐turnover uraemic bone disease. However, as the number of patients with repeat bone biopsies was small, these findings need to be confirmed in a larger study. Further studies are also needed to evaluate whether or not the changes in IGF system components play a role in decreased bone cell activity in patients on dialysis using the AN‐69 polyacrylonitrile membrane." @default.
• W2100027947 created "2016-06-24" @default.
• W2100027947 creator A5008823120 @default.
• W2100027947 creator A5028164857 @default.
• W2100027947 creator A5031734328 @default.
• W2100027947 creator A5039333052 @default.
• W2100027947 creator A5044340801 @default.
• W2100027947 creator A5051847656 @default.
• W2100027947 creator A5054497725 @default.
• W2100027947 creator A5081877056 @default.
• W2100027947 creator A5087315474 @default.
• W2100027947 creator A5091576909 @default.
• W2100027947 date "2001-06-01" @default.
• W2100027947 modified "2023-10-18" @default.
• W2100027947 title "Effect of type of dialysis membrane on bone in haemodialysis patients" @default.
• W2100027947 cites W1975947406 @default.
• W2100027947 cites W1977173084 @default.
• W2100027947 cites W1985198946 @default.
• W2100027947 cites W1986208951 @default.
• W2100027947 cites W1993859462 @default.
• W2100027947 cites W2015862698 @default.
• W2100027947 cites W2041203073 @default.
• W2100027947 cites W2063048904 @default.
• W2100027947 cites W2067420381 @default.
• W2100027947 cites W2080362119 @default.
• W2100027947 cites W2082228528 @default.
• W2100027947 cites W2088278398 @default.
• W2100027947 cites W2104223319 @default.
• W2100027947 cites W2107978025 @default.
• W2100027947 cites W2127294226 @default.
• W2100027947 cites W2152726285 @default.
• W2100027947 cites W2159594047 @default.
• W2100027947 cites W2160856085 @default.
• W2100027947 cites W2162370884 @default.
• W2100027947 cites W2320592110 @default.
• W2100027947 doi "https://doi.org/10.1093/ndt/16.6.1230" @default.
• W2100027947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11390725" @default.
• W2100027947 hasPublicationYear "2001" @default.
• W2100027947 type Work @default.
• W2100027947 sameAs 2100027947 @default.
• W2100027947 citedByCount "4" @default.
• W2100027947 crossrefType "journal-article" @default.
• W2100027947 hasAuthorship W2100027947A5008823120 @default.
• W2100027947 hasAuthorship W2100027947A5028164857 @default.
• W2100027947 hasAuthorship W2100027947A5031734328 @default.
• W2100027947 hasAuthorship W2100027947A5039333052 @default.
• W2100027947 hasAuthorship W2100027947A5044340801 @default.
• W2100027947 hasAuthorship W2100027947A5051847656 @default.
• W2100027947 hasAuthorship W2100027947A5054497725 @default.
• W2100027947 hasAuthorship W2100027947A5081877056 @default.
• W2100027947 hasAuthorship W2100027947A5087315474 @default.
• W2100027947 hasAuthorship W2100027947A5091576909 @default.
• W2100027947 hasBestOaLocation W21000279471 @default.
• W2100027947 hasConcept C126322002 @default.
• W2100027947 hasConcept C126894567 @default.
• W2100027947 hasConcept C131075544 @default.
• W2100027947 hasConcept C134018914 @default.
• W2100027947 hasConcept C146562846 @default.
• W2100027947 hasConcept C160160445 @default.
• W2100027947 hasConcept C170033053 @default.
• W2100027947 hasConcept C170493617 @default.
• W2100027947 hasConcept C181199279 @default.
• W2100027947 hasConcept C185592680 @default.
• W2100027947 hasConcept C202751555 @default.
• W2100027947 hasConcept C2776033226 @default.
• W2100027947 hasConcept C2776169692 @default.
• W2100027947 hasConcept C2776541429 @default.
• W2100027947 hasConcept C2776699218 @default.
• W2100027947 hasConcept C2778260815 @default.
• W2100027947 hasConcept C2778653478 @default.
• W2100027947 hasConcept C2779978075 @default.
• W2100027947 hasConcept C2780644872 @default.
• W2100027947 hasConcept C2781208988 @default.
• W2100027947 hasConcept C519063684 @default.
• W2100027947 hasConcept C55493867 @default.
• W2100027947 hasConcept C673006 @default.
• W2100027947 hasConcept C71924100 @default.
• W2100027947 hasConceptScore W2100027947C126322002 @default.
• W2100027947 hasConceptScore W2100027947C126894567 @default.
• W2100027947 hasConceptScore W2100027947C131075544 @default.
• W2100027947 hasConceptScore W2100027947C134018914 @default.
• W2100027947 hasConceptScore W2100027947C146562846 @default.
• W2100027947 hasConceptScore W2100027947C160160445 @default.
• W2100027947 hasConceptScore W2100027947C170033053 @default.
• W2100027947 hasConceptScore W2100027947C170493617 @default.
• W2100027947 hasConceptScore W2100027947C181199279 @default.
• W2100027947 hasConceptScore W2100027947C185592680 @default.
• W2100027947 hasConceptScore W2100027947C202751555 @default.
• W2100027947 hasConceptScore W2100027947C2776033226 @default.
• W2100027947 hasConceptScore W2100027947C2776169692 @default.
• W2100027947 hasConceptScore W2100027947C2776541429 @default.
• W2100027947 hasConceptScore W2100027947C2776699218 @default.
• W2100027947 hasConceptScore W2100027947C2778260815 @default.
• W2100027947 hasConceptScore W2100027947C2778653478 @default.
• W2100027947 hasConceptScore W2100027947C2779978075 @default.
• W2100027947 hasConceptScore W2100027947C2780644872 @default.
• W2100027947 hasConceptScore W2100027947C2781208988 @default.
• W2100027947 hasConceptScore W2100027947C519063684 @default.

• next